Disease Awareness Information: The Xiaflex Dupuytren's Dilemma
This article was originally published in RPM Report
Is FDA trying effectively to ban the practice of providing disease awareness information in promotoional materials? A recent letter to Auxilium on promotional materials for the company's drug for Dupuytren Disease (Xiaflex) suggests FDA is still looking closely at how companies describe disease states compared to a product's labeled indications.
You may also be interested in...
Letter to Dysport clinical investigator claims promotional violations in magazine interviews. Do clinical investigators really sign away their right to free speech when they conduct a clinical trial for a drug company?
An HHS departmental appeals board decision finds Purdue executives at fault despite plea and convictions based solely on the Dotterweich and Park doctrines
The Food and Drug Administration is increasingly replacing rulemaking with guidance. The outcome of two legal cases indicates how that trend may be undercutting the administration's message of transparency.